Elanco Animal Health Incorporated (ELAN)

From the record

Elanco Animal Health Incorporated's filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Elanco Animal Health Incorporated's 10 filed years say what it did: revenue went from $2.9 billion in fiscal 2016 to $4.7 billion in fiscal 2025, up 5.5% a year; it rose in 7 of 9 years; the deepest fall was 7% from fiscal 2021 to fiscal 2022; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Elanco Animal Health Incorporated's diluted share count grew about 0.5% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale (1 under scheduled 10b5-1 plans) and 11 purchases of their own stock on the open market in the year to 2026-11-03, buying about $3 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Elanco Animal Health Incorporated lost about 4 cents for every dollar of shareholders' money, and gross profitability: its products earned about 19 cents per dollar of everything the company owns. Leverage: it owed about 51 cents per dollar of assets, and net share issuance: its share count grew 0.5% over the year (the filed statements).

From the record

Elanco Animal Health Incorporated's standing among 315 graded names in its industry family: revenue of $4.7 billion in fiscal 2025 ranks in the top 6% by size; a net margin of -4.9% ranks in the top 27%; revenue growth of 2.2% a year over the last 3 filed years ranks in the bottom 42% (its annual reports).

From the record

Elanco Animal Health Incorporated's leadership, from its insiders' filings and its current reports: the chief executive on the record is Simmons, Jeffrey N (PRESIDENT, CEO AND DIRECTOR, as filed), filing under that title since 2018-09-19, 8.2 years (top 22% of its family); the 21 officers and directors filing in the last fifteen months have been on the record a median of 7.7 years (top 22%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 21 people in charge now (top 21%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Elanco Animal Health Incorporated's room to grow, from the newest filed statements (fiscal 2025): cash of $545 million against debt of $3.8 billion leaves -24.1% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 6% of revenue (top 24%); a gross margin of 55% (bottom 30%); research spending of 7.8% of revenue (bottom 11%) (its annual report).

From the record

Elanco Animal Health Incorporated's growth drivers, from the filed years to fiscal 2025: revenue grew 2.2% a year over the last three filed years against 5.5% over all 10, slowing (bottom 47% of its family); the newest year grew 6.2% (bottom 48%); research spending grew 4.7% a year (top 47%); capital spending grew 17.3% a year (top 26%) (its annual reports). Elanco Animal Health Incorporated reported 5 product lines in fiscal 2025: Pet Health at $2.3 billion (49%), Cattle at $1.1 billion (24%), Poultry at $858 million (18%), and 2 more; 5 of 5 grew against the year before (its annual report).

From the record

Elanco Animal Health Incorporated's newest year against its own record: revenue of $4.7 billion in fiscal 2025 came in 5.9% above the $4.5 billion its prior three years' pace pointed to (top 37% of its family); net income of $232 million against a prior three-year average of $324 million (top 42%); a net margin of -4.9% against -7.3% before (bottom 39%) (its annual reports).